SERG Technologies, a spin-out of Imperial College, London, has raised £1.6 million in funding to help it bring its device for early diagnosis and monitoring of Parkinson’s to market. The funding will be used to help the NuRO platform gain regulatory approval for sale in the UK and US, as well as to work on a potential treatment.
NuRO utilises acoustic sensors to detect a patient’s movements and assess the state of their muscles. This aims to provide a more objective method of identifying early symptoms of Parkinson’s disease, including tremors, limb stiffness of slowness of movement, and gauge their severity.
It is hoped that the platform could be used to provide early diagnosis, as well as continuous monitoring to enable doctors to manage patients more effectively. The company says there is also potential for the device to deliver electrical stimulation to muscles, which could help to relieve symptoms.
SERG was founded by Dr Ravi Vaidyanathan and Dr Sam Wilson in 2019. The latest funding round saw it secure investment from private investors, the Imperial College Innovation Fund, Mercia, Velocity Partners, Newable and a Japanese corporation.
In 2019, the company raised £450,000 in funding from angel investors and Velocity Partners. This was used to develop its initial platform and commence clinical trials, which have so far involved 100 patients and returned positive data from initial results. SERG has also won £1.5 million in total grant funding to date.
CEO Dr Christos Kapatos said: “More people are being diagnosed with Parkinson’s and increasingly at a younger age. The disease is incurable, debilitating and expensive to treat. Our connected platform enables remote, patient-specific assessment of all motor symptoms and delivers actionable insights that optimise treatment and promote lifestyle changes, thus increasing patient mobility and independence. Our vision is to enable people with Parkinson’s and other neurodegenerative diseases and movement disorders to live healthier lives.”